Skandinaviska Enskilda Banken AB publ Has $8.59 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

Skandinaviska Enskilda Banken AB publ increased its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 16.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 182,126 shares of the biopharmaceutical company’s stock after buying an additional 26,332 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.15% of Cytokinetics worth $8,585,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Jones Financial Companies Lllp boosted its holdings in shares of Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 374 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Cytokinetics in the 4th quarter valued at approximately $29,000. AlphaQuest LLC boosted its holdings in shares of Cytokinetics by 113,500.0% in the 4th quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 1,135 shares during the last quarter. J.Safra Asset Management Corp boosted its holdings in shares of Cytokinetics by 62.1% in the 4th quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 671 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Cytokinetics by 85.8% in the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 842 shares during the last quarter.

Insider Activity at Cytokinetics

In related news, EVP Andrew Callos sold 3,341 shares of the business’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $43.27, for a total value of $144,565.07. Following the completion of the transaction, the executive vice president now owns 64,434 shares of the company’s stock, valued at $2,788,059.18. The trade was a 4.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $49.32, for a total value of $98,640.00. Following the completion of the transaction, the executive vice president now owns 116,071 shares in the company, valued at approximately $5,724,621.72. This represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,153 shares of company stock valued at $1,300,870 over the last quarter. 3.40% of the stock is owned by corporate insiders.

Cytokinetics Stock Down 0.1 %

CYTK stock opened at $44.36 on Friday. The company has a market cap of $5.25 billion, a PE ratio of -8.25 and a beta of 0.95. The business has a 50-day simple moving average of $46.34 and a 200 day simple moving average of $50.39. Cytokinetics, Incorporated has a 52 week low of $40.53 and a 52 week high of $75.71. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.03. The company had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.26 million. Sell-side analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Mizuho increased their price target on Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. JMP Securities restated a “market outperform” rating and issued a $78.00 price target on shares of Cytokinetics in a research note on Friday, February 7th. Citigroup assumed coverage on Cytokinetics in a research note on Friday, February 7th. They issued a “buy” rating and a $86.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a research note on Friday, February 28th. Finally, Royal Bank of Canada increased their price target on Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $82.00.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.